Spigot opens on FY ’09 money
President Obama signs fiscal year 2009 omnibus appropriations bill March 11. FDA will have $2.6 billion to spend this fiscal year, including $777.4 million for CDER and related field activities, with $41.4 million reserved for the Office of Generic Drugs and $271.5 million for CBER and related field activities
You may also be interested in...
Seattle Genetics holds the award for fastest supplemental approval (11 days) and fastest new molecular entity approval (119 days) under the US FDA's RTOR program, according to the Pink Sheet's Performance Tracker.
Technology modernization efforts, the expansion of cloud-based submission capabilities, and the ongoing COVID-19 pandemic could serve as catalysts to broaden FDA’s Real-Time Oncology Review program beyond cancer therapeutics, Pfizer exec Richard Jahn says.
Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.